Search results
Results from the WOW.Com Content Network
If a pregnant woman presents in labor with an unknown HIV status and a positive rapid HIV test result or an infant has a high risk of HIV transmission in utero (for example, the mother was not taking antiretroviral drugs in the pre-pregnancy period or during pregnancy, the mother had not achieved viral suppression, or the mother experienced an ...
A report from early 2013 revealed that a female baby born with the HIV virus displayed no sign of the virus two years after high doses of three antiretroviral drugs were administered within 30 hours of her birth.
WHO Disease Staging System for HIV Infection and Disease was first produced in 1990 by the World Health Organization [1] and updated in 2007. [2] It is an approach for use in resource limited settings and is widely used in Africa and Asia and has been a useful research tool in studies of progression to symptomatic HIV disease .
This is an important time for prevention, as acquiring HIV during pregnancy increases the risk of transmission to the infant. [6] Global oral PrEP accessibility for women, including those who are either pregnant or breastfeeding, is limited. In addition, there is minimal research on the effects of injectable PrEP and pregnancy outcomes. [21]
HIV/AIDS has become a chronic rather than an acutely fatal disease in many areas of the world. [203] Prognosis varies between people, and both the CD4 count and viral load are useful for predicted outcomes. [32] Without treatment, average survival time after infection with HIV is estimated to be 9 to 11 years, depending on the HIV subtype. [6]
WHO Disease Staging System for HIV Infection and Disease in Adults and Adolescents was first produced in 1990 by the World Health Organization [1] and updated in September 2005. It is an approach for use in resource limited settings and is widely used in Africa and Asia and has been a useful research tool in studies of progression to ...
It is commonly used in pregnancy and appears to be safe for the fetus. [6] ZDV is of the nucleoside analog reverse-transcriptase inhibitor (NRTI) class. [6] It works by inhibiting the enzyme reverse transcriptase that HIV uses to make DNA and therefore decreases replication of the virus. [6] Zidovudine was first described in 1964. [7]
Transmission-based precautions are infection-control precautions in health care, in addition to the so-called "standard precautions". They are the latest routine infection prevention and control practices applied for patients who are known or suspected to be infected or colonized with infectious agents, including certain epidemiologically important pathogens, which require additional control ...